<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

ConvaTec IPO Prospectus Cites BioMedGPS SmartTRAK as Source

Posted by Sharon O'Reilly on 11/1/16 9:00 AM

Convatecc_Logo.pngIn ConvaTec's IPO prospectus released October 26, 2016, BiomedGPS was cited 25 times as a source for their market estimates and charts 


Among the many citations:

"Key manufacturers of silver dressings include ConvaTec, Smith & Nephew, Molnlycke and Coloplast with ConvaTec in the number one position globally with approximately 31 percent market share in 2015 (source: BioMedGPS)"

"The Group entered the foam sub-segment in 2012 and grew to six percent market share in 2015 Molnlycke is currently the global leader with its range of Mepilex  dressings and had 41 per cent market share in 2015  (source: BioMedGPS)"

"Advanced Wound Care accounted for 32.5 percent of the Group’s revenue in 2015 and had an addressable market of $5.0 billion, which is expected to grow at five to six percent per annum between  2015 and 2020  (sources: BioMedGPS and FMI)."

"Antimicrobial/silver dressings was a $0.6 billion global market in 2015, and is expected to grow at a CAGR of six percent between 2015 and 2020 (source: BioMedGPS). Silver dressings account for 86 percent of the global antimicrobial dressings segment (source: BioMedGPS) and are the most preferred antimicrobial dressings in developed countries including the United States. There is  an  emerging awareness of the impact of biofilms  associated with recalcitrant wounds  in  this segment. These dressings are also increasingly being used to treat other indications (e.g. surgical)."

To keep up with all the news and analysis click below to subscribe to the SmartTRAK blog.  

Subscribe to Blog

Topics: Your SmartTRAK News

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts